Elizabeth – Interview 27
Elizabeth was invited to join a trial of chemotherapy for ovarian cancer, but decided not to take part as she knew which treatment she would prefer and did not want to be randomised to another group. She felt the consultant was cross about her decision.
Elizabeth was diagnosed with early-stage ovarian cancer in 1996. She needed an operation and was told she should also have a course of chemotherapy. While she was still in hospital recovering from surgery, the consultant came to ask if she would take part in a trial. This would have been comparing the current standard chemotherapy course with a new combination of drugs. She was given three weeks to think about it.
Elizabeth and her family thought about it, but she felt for a number of reasons she did not want to take part. One reason was that, unlike many women with ovarian cancer, she had been diagnosed at an early stage and therefore felt it was not necessary to have the extra chemotherapy. She also thought that because she was not a typical patient this would affect the validity of the trial results. Another reason was that one of the side effects of the new combination of drugs would have been losing her hair. Both she and her son would have found this very distressing, and she would have felt she had lost her identity. She did think briefly about saying yes, and then seeing which group she was randomised to, thinking she could withdraw if she was allocated to the group getting the combination therapy, but then felt that would not be fair on the staff running the trial.
When she went back for her next appointment she therefore told the registrar she had decided not to take part. The registrar was supportive and understanding, but said she had to call in the consultant to tell him. Elizabeth’s memory is that the consultant was quite cross with her about her decision, and implied she was only declining for selfish or trivial reasons, because she was worried about losing her hair. Elizabeth was upset by his reaction and worried that it might affect the quality of care she received because she had refused, although in fact it did not. She still feels not going on the trial was the right decision for her at the time.
She feels clinical staff need to show more understanding of how vulnerable patients feel making such a serious decision at a time when they already feel worried and upset by their illness. She thinks it is important staff respect individuals; reasons for making their own choices. She thinks medical research is important and clinical trials are valuable, but staff must raise it with great sensitivity. Elizabeth also feels more should be done to feed back to patients who have taken part in a trial what the results are in the end, and also to provide them with proper support, in case the results show that the treatment they had was not in fact effective. This is still a valuable research finding, but for an individual who has experienced unpleasant side effects and given up time for a trial, it could be upsetting news. It is better to tell them but with appropriate support than to leave them to find out on their own on the internet.